In the prostate cancer TME, macrophages primarily polarize toward the M1 state and utilize CXCL12/CXCR4 crosstalk to chemoattract peripheral CD8+ effector T cells, which target and kill cancer cells, thereby impeding tumor progression. Here, CXCL12 is linked to prostate carcinoma.